about
Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal AntibodiesBiosimilar insulins: a European perspectiveMonoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published EvidenceBiosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.Etanercept biosimilarsNew frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.Etanercept for the treatment of non-radiographic axial spondyloarthritis.Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational StudyInfliximab Biosimilars: A Promising but Unusual Treatment for Mycobacterial Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients.The sweet spot for biologics: recent advances in characterization of biotherapeutic glycoproteins.Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans.
P2860
Q26738325-D0EEB686-CDB9-4E13-A281-0DF69DA4BE0FQ27026596-13A0DAF6-AA1E-47CE-9F8E-05871BD3FBF7Q28078423-07349539-6F8A-47F5-AE3F-6FE60797C92FQ30393052-991934D1-77B2-4418-A840-A3755370F462Q35020358-CD3E5E01-A061-4EED-A994-61936AF3B06DQ38300338-7B6A7A50-C222-44EF-8194-FA00342282C5Q38703849-D9118A0E-3AD7-4D40-890A-301A5319DB1BQ41439263-4A7EA82C-ACD8-458C-8C2B-976A03A52D47Q41694401-F7A4B303-05EB-489A-9E31-7B2F2F34426AQ47410418-3BC9DBB1-C998-45F8-9947-EBA009A124EEQ48256716-F1FE176B-38ED-4E50-B7E9-015230DBC968
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Clinical considerations for biosimilar antibodies.
@ast
Clinical considerations for biosimilar antibodies.
@en
type
label
Clinical considerations for biosimilar antibodies.
@ast
Clinical considerations for biosimilar antibodies.
@en
prefLabel
Clinical considerations for biosimilar antibodies.
@ast
Clinical considerations for biosimilar antibodies.
@en
P2860
P1433
P1476
Clinical considerations for biosimilar antibodies.
@en
P2093
Håkan Mellstedt
P2860
P356
10.1016/S1359-6349(13)70001-6
P577
2013-12-01T00:00:00Z